Contact us | Add to favorites | Association address | Related link
Welcome to 2023/11/5 22:38:12
homepage About the Association Association dynamics Policies and regulations Beijing Medicine Express Industry dynamics International information Economic analysis Thematic discussion At your service Training registration Branch garden Social organization
Job column
  Current Location:首页>>International information>>International information
Pradaxa(Dabigatranate) : The first drug to treat venous thromboembolism (VTE) and prevent recurrence in pediatric patients
Boehringer Ingelheim recently announced,The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review opinion,Recommended for approval of the oral anticoagulant Pradaxa (dabigatran etexilate),Dabigatran ester,For pediatric patients from birth to under 18 years of age,Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE。
If the proposed indication is approved by the European Commission (EC), pediatric patients and healthcare professionals in Europe will be able to treat this oral anticoagulant, the risk benefit of which has been fully evaluated by the regulatory authorities。
Currently, there are no approved treatments to treat or prevent VTE in children。The current standard of care (SOC) is associated with a range of limitations, including the need for frequent monitoring of anticoagulant levels or the burden of daily injections。
This regimen can be taken orally, does not require routine laboratory monitoring or dose-titration, and formulations for specific age groups, including younger patients, are available。
(Information source: BioValley)(Source: China News Service)
(2020/11/25 13:57:07 Read 39150 times)

Beijing Pharmaceutical Industry Association public number

Copyright 2003-2016 percentred by Beijing Pharmaceutical Professiion Association All Rights Reserved
Copyright Beijing Pharmaceutical Industry Association. All rights reserved
ICP record number: Beijing ICP No. 11016038-1